Bank of America Securities Maintains a Sell Rating on Amgen (AMGN)

Amgen Inc. (NASDAQ:AMGN) is one of the best large cap value stocks to buy now. On September 26, Bank of America Securities analyst Tim Anderson maintained a Sell rating on Amgen Inc. (NASDAQ:AMGN) and set a price target of $272.00.

The same day, Amgen Inc. (NASDAQ:AMGN) announced a $650 million expansion of its U.S. manufacturing network, creating hundreds of new jobs.

Management reported that the planned investment is anticipated to create around 750 jobs, and would support increased drug production at its biologics manufacturing facility in Juncos along with integrating “innovative advanced technologies throughout the operations process”.

Amgen Inc. (NASDAQ:AMGN) is a biotechnology company that discovers, develops, manufactures, and markets human therapeutics. It delivers new therapies for patients with complex cancers, especially in areas with significant unmet needs.

While we acknowledge the potential of AMGN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.